Participated · Series C · Mar 2021

EpimAb Biotherapeutics is a clinical-stage biopharmaceutical company developing proprietary bispecific antibody therapeutics using its FIT-Ig® (Fabs-In-Tandem Immunoglobulin) platform. The company focuses on oncology and other high‑value therapeutic areas and is building a pipeline of both clinical and preclinical bispecific programs. Its lead candidates—EMB-01 (EGFR/cMET), EMB-02 (PD-1/LAG-3) and EMB-06 (CD3/BCMA)—are advancing through clinical development in China, the U.S. and Australia. Proceeds from the Series C will fund ongoing clinical development of these three assets and expand the company’s pipeline of novel bispecifics and other biologics. EpimAb maintains research and manufacturing facilities in Shanghai and Suzhou and intends to selectively license platform and pipeline assets to partners worldwide. The company emphasizes translating its FIT-Ig platform into differentiated clinic-ready molecules with global potential. EpimAb Biotherapeutics is a Shanghai-based R&D biotech focused on generating bispecific antibody therapeutics via its proprietary FIT-Ig® (Fabs-In-Tandem Immunoglobulin) platform. The company is advancing a clinical PhI/II program, EMB01, and is building a pipeline concentrated on immuno-oncology and other high-unmet-need areas. Management includes founder and CEO Chengbin Wu, COO/CBO Stephan Lensky, and CMO Bin Peng, who lead discovery, financing/BD, and translational/clinical development respectively. With the Series B close, EpimAb plans to expand development and manufacturing capacity, adding a new CMC site in Suzhou for process development and pilot manufacturing. The company also pursues selective licensing of its platform to diversify its pipeline and partner globally. Financially, the Series B brings recent financing to $74M and total funding to over $100M to support near-term clinical and manufacturing initiatives. EpimAb Biotherapeutics is a privately owned biopharmaceutical R&D company based in Shanghai, founded in 2015, focused on generating bispecific molecules with antibody-like properties using its FIT-Ig® (Fabs-In-Tandem Immunoglobulin) platform. The FIT-Ig technology is designed to be more potent, less immunogenic and easier to manufacture. EpimAb is building a pipeline of novel bispecific antibody therapeutics centered on immuno-oncology and other areas with high unmet medical need, and seeks to diversify via selective licensing and strategic partnerships. The company says its platform was validated through early partnerships with biopharmaceutical companies in China and abroad. Management plans to advance its lead oncology program toward the clinic, anticipating submission of an IND and the start of a first clinical trial in 2018. Leadership includes founder and CEO Dr. Chengbin Wu, inventor of FIT-Ig®, and Dr. Stephan Lensky as COO and CBO.

Participated · Series C · Oct 2017

Ninebot is a Beijing-based company providing mobile robotics and intelligent short-distance electric transportation solutions. It operates as the Segway & Ninebot Group after acquiring Segway Inc. in March 2015 and focuses on personal transportation and Segway Robotics. Led by founder and CEO Lufeng Gao, the company launched Segway Loomo, a general-purpose robotic service platform, earlier this year. In October 2017 Ninebot raised the equivalent of $100M in Series C financing to support its expansion. The company intends to use the funds to further enhance deployment of its business around the world. Ninebot is a Beijing-based maker of short-distance personal transportation equipment. The company focuses on R&D, production, sales and services of intelligent transport devices including unicycles, two-wheel self-balancing vehicles and other smart personal-transportation robotics products. In April 2015 Ninebot acquired Segway. Post-acquisition the company serves customers in more than 100 countries and holds over 60% of the global market share in personal transporters. Ninebot reports more than 400 core patents, representing over 90% of worldwide patents in the space. The company received a venture capital investment from Intel Capital (amount undisclosed). Ninebot is a Beijing-based company operating in the personal transportation mobility device sector. It announced the acquisition of Segway, which will become a wholly owned subsidiary while both brands remain separate. Ninebot says its products are independently developed and manufactured in China and that it independently owns its intellectual property, offering comparable quality at lower prices than imported brands. Founder and CEO Gao Lufeng said the company will apply technologies including electric driving, mobile internet, and man-machine interaction to future products and expand its product roster. Ninebot raised $80 million in funding from investors including Xiaomi, Sequoia Capital, and the Shunwei Foundation. The company had been named in a prior trade complaint by Segway alleging patent infringement, but the two companies appear to have put that dispute behind them.

Led · Series D · Aug 2017

CF PharmTech is a fully integrated specialty pharmaceutical company that develops and manufactures inhalation products and respiratory drugs. The company focuses on treatments for respiratory diseases and operates facilities for drug development and production. It raised a US$50M Series F financing to support its programs. The company followed a US$90M Series E in January 2020; together those rounds amount to nearly US$140M of equity investment within six months. CF PharmTech says it will use the Series F proceeds to accelerate commercialization of its inhalation products. The company positions itself to provide affordable, high-quality respiratory drugs globally. CF PharmTech is a pharmaceutical company dedicated to respiratory health, with state-of-the-art R&D and manufacturing facilities for inhalation products. The company has built a pipeline of more than 20 products aimed at China and global markets. It raised a $90M Series E to advance its product pipeline. The firm intends to use the funds to bring products in its pipeline to market. CF PharmTech operates from Shuzhou, China, and emphasizes inhalation therapeutics and related manufacturing capabilities. The article does not disclose revenue or user metrics. CF PharmTech is a Suzhou, China-based specialty pharmaceutical company focused on the development, manufacturing and commercialization of inhalation products, including metered dose inhalers, inhalation powders, nasal sprays and blow-fill-seal products. The company has established research and manufacturing facilities to advance its product development. Founded by seasoned industry experts and entrepreneurs from the US pharmaceutical industry, CF PharmTech also provides CDMO services. It intends to use new financing to expedite submission of its product pipeline for regulatory approvals in China and abroad and to expand its CDMO services to international clients. The company raised $65M in a Series D financing to support these plans.

Led · Series D · Nov 2016

Innovent Biologics is a Hong Kong-based biotech that develops and manufactures affordable complex biopharmaceutical products. Founded in August 2011 by Dr. Michael Yu, the company has built a portfolio targeting cancer, ophthalmology, autoimmune disorders, and cardiovascular diseases. It currently has 16 molecules in research, seven in clinical development, four in Phase III and one with a BLA submitted to the CFDA. Five molecules have been selected under the national mega innovative program and one received a precision medicine research grant under China's National Key R&D Plan. Innovent has a large-scale manufacturing base compliant with CFDA, FDA and EMA GMP standards. The company intends to use the funds to speed up and expand clinical programs and to build a commercial team. Innovent Biologics is a Shanghai, China–based biopharmaceutical company dedicated to the discovery, development, manufacturing and commercialization of biologics. Founded in August 2011 by Michael Yu, Ph.D., the company has built a portfolio of 12 product candidates targeting cancer, autoimmune disorders, ophthalmology and cardiovascular diseases. Innovent has filed eight IND applications and has four products in clinical development, three of which are in phase 3 trials. The company operates under rigorous cGMP requirements and is expanding its manufacturing capacity. It intends to use new funding to continue development of innovative biopharmaceutical products, expand manufacturing, and support ongoing operations. Innovent Biologics is a Shanghai-based biopharmaceutical company dedicated to the development and manufacturing of complex biologics. Led by co-founder, president and CEO Michael Yu, the company is advancing an internal pipeline of eight antibody products, including one approved IND and four additional filed applications. Innovent aims to market its portfolio in the Chinese market and internationally while meeting EMEA and FDA/cGMP standards. Its strategy combines advancing proprietary biologic drugs with establishing in- and out-licensing agreements with global pharmaceutical and biotech companies. The company plans to use newly raised funds to advance its pipeline and grow operations. Innovent raised capital to support these plans and expand its development and manufacturing activities.